NASDAQ:IMMUImmunomedics Stock Price, Forecast & News

$30.18

-1.31 (-4.16 %)

(As of 06/4/2020 04:00 PM ET)

Add

Compare

Today's Range

$29.55

Now: $30.18▼

$32.00

50-Day Range

$19.92

MA: $29.97▼

$34.84

52-Week Range

$8.80

Now: $30.18▼

$35.47

Volume4.43 million shs

Average Volume3.76 million shs

Market Capitalization$6.97 billion

P/E RatioN/A

Dividend YieldN/A

Beta3.35

Immunomedics, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. Its advanced antibody-drug conjugates are sacituzumab govitecan and labetuzumab govitecan, which are in advanced trials for various solid tumors and metastatic colorectal cancer, respectively. The company focuses on commercializing sacituzumab govitecan as a third-line therapy for patients with metastatic triple-negative breast cancer in the United States. The company also develops IMMU-140, a humanized antibody directed against an immune response target. Its other product candidates include products for the treatment of cancer and autoimmune diseases, including epratuzumab, an anti-CD22 antibody; veltuzumab, an anti-CD20 antibody; milatuzumab, an anti-CD74 antibody; and IMMU-114, a humanized anti-HLA-DR antibody. Immunomedics, Inc. has clinical collaboration with AstraZeneca and MedImmune, to evaluate Imfinzi, a human monoclonal antibody against PD-L1, with sacituzumab govitecan as a frontline treatment of patients with TNBC and urothelial cancer; collaboration agreement with The Bayer Group for the development of epratuzumab; clinical and preclinical collaborations with academic cancer institutions, identifying new cancer indications for sacituzumab govitecan and the biology of the Trop-2 antigen; and research collaboration with the Memorial Sloan Kettering Cancer Center to investigate Sacituzumab Govitecan and Labetuzumab Govitecan in preclinical cancer models. Immunomedics, Inc. has a partnership agreement with the Samsung BioLogics Co., Ltd. to manufacture hRS7, an Immunomedics proprietary humanized antibody. The company was founded in 1982 and is headquartered in Morris Plains, New Jersey.

Beat the Market (BTM) Rank^™

3.4 Analyst's Opinion

Consensus Rating
Immunomedics has received a consensus rating of Buy. The company's average rating score is 2.85, and is based on 11 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $34.00, Immunomedics has a potential upside of 12.7% from its current price of $30.18.
Amount of Analyst Coverage
Immunomedics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.4 Community Rank

Outperform Votes
Immunomedics has received 430 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Immunomedics has received 457 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Immunomedics has received 51.52% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Immunomedics and other stocks. Vote “Outperform” if you believe IMMU will outperform the S&P 500 over the long term. Vote “Underperform” if you believe IMMU will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Immunomedics does not currently pay a dividend.
Dividend Growth
Immunomedics does not have a long track record of dividend growth.

4.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Immunomedics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $49,875,000.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 9.40% of the stock of Immunomedics is held by insiders.
Percentage Held by Institutions
76.37% of the stock of Immunomedics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Immunomedics are expected to grow in the coming year, from ($1.47) to ($0.87) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Immunomedics is -16.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Immunomedics is -16.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Immunomedics has a P/B Ratio of 21.87. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

2.09 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Diagnostic substances

Sub-IndustryBiotechnology

SectorMedical

Current SymbolNASDAQ:IMMU

Previous Symbol

CUSIP45290710

CIK722830

Webwww.immunomedics.com

Phone973-605-8200

Debt

Debt-to-Equity Ratio0.05

Current Ratio8.37

Quick Ratio8.37

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$290,000.00

Price / Sales24,029.52

Cash FlowN/A

Price / Cash FlowN/A

Book Value$1.38 per share

Price / Book21.87

Profitability

EPS (Most Recent Fiscal Year)($1.84)

Net Income$-357,190,000.00

Net MarginsN/A

Return on Equity-246.01%

Return on Assets-67.35%

Miscellaneous

Employees346

Outstanding Shares230,900,000

Market Cap$6.97 billion

Next Earnings DateN/A

OptionableOptionable

Receive IMMU News and Ratings via Email

Sign-up to receive the latest news and ratings for IMMU and its competitors with MarketBeat's FREE daily newsletter.

Immunomedics (NASDAQ:IMMU) Frequently Asked Questions

How has Immunomedics' stock been impacted by COVID-19 (Coronavirus)?

Immunomedics' stock was trading at $13.38 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, IMMU stock has increased by 125.6% and is now trading at $30.18. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Immunomedics?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immunomedics in the last year. There are currently 2 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Immunomedics.

How were Immunomedics' earnings last quarter?

Immunomedics, Inc. (NASDAQ:IMMU) issued its quarterly earnings data on Wednesday, May, 6th. The biopharmaceutical company reported ($0.44) EPS for the quarter, beating analysts' consensus estimates of ($0.46) by $0.02. During the same quarter in the prior year, the company earned ($0.46) earnings per share. View Immunomedics' earnings history.

What price target have analysts set for IMMU?

13 equities research analysts have issued 1-year price targets for Immunomedics' stock. Their forecasts range from $22.00 to $54.00. On average, they anticipate Immunomedics' share price to reach $34.00 in the next twelve months. This suggests a possible upside of 12.7% from the stock's current price. View analysts' price targets for Immunomedics.

What are Wall Street analysts saying about Immunomedics stock?

Here are some recent quotes from research analysts about Immunomedics stock:

1. According to Zacks Investment Research, "Immunomedics got a significant boost with the recent FDA approval for its lead drug, Trodelvy (sacituzumabgovitecan-hziy), an antibody-drug conjugate (ADC), for the treatment of patients with mTNBC. The successful commercialization of the drug will bring in sales for the company. Meanwhile, Trodelvy is being evaluated in several label expansion studies, including earlier-line settings for breast cancer and other cancer indications. A late-stage study on the candidate was recently halted due to its compelling efficacy. Immunomedics is also evaluating acituzumab in other cancer types. However, competition is stiff from bigwigs in the market. Pipeline setbacks will also weigh on shares." (4/24/2020)
2. HC Wainwright analysts commented, "We remind investors that sacituzumab previously achieved a 31% 6.8-month median progression-free survival (mPFS) which, in our view, compares favorably to chemotherapy’s effect in this patient population (10-13% ORR and 3-4 month mPFS). Accordingly, we reiterate our Buy rating, while reducing our 12-month price target from $28 to $26 to account for the removal of the second- line HR+, HER2- mBC setting from our assumptions. IMMU-132 filing resubmission remains on track for early 4Q19." (8/8/2019)

Has Immunomedics been receiving favorable news coverage?

Press coverage about IMMU stock has been trending somewhat positive recently, according to InfoTrie. InfoTrie scores the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Immunomedics earned a daily sentiment score of 0.7 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutImmunomedics.

Who are some of Immunomedics' key competitors?

Some companies that are related to Immunomedics include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL). View all competitors.

What other stocks do shareholders of Immunomedics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Immunomedics investors own include Celgene (CELG), Seattle Genetics (SGEN), Synergy Pharmaceuticals (SGYP), NVIDIA (NVDA), Micron Technology (MU), ImmunoGen (IMGN), Gilead Sciences (GILD), Netflix (NFLX), Novavax (NVAX) and Advanced Micro Devices (AMD).

Who are Immunomedics' key executives?

Immunomedics' management team includes the following people:

Dr. Behzad Aghazadeh Ph.D., Exec. Chairman (Age 48)
Dr. Morris Z. Rosenberg, Chief Technology Officer (Age 59)
Mr. Scott A. Canute MBA, Exec. Director (Age 58)
Mr. Brendan Delaney, Chief Commercial Officer (Age 44)
Dr. Robert Iannone, Chief Medical Officer and Head of R&D (Age 52)

What is Immunomedics' stock symbol?

Immunomedics trades on the NASDAQ under the ticker symbol "IMMU."

Who are Immunomedics' major shareholders?

Immunomedics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.37%), State Street Corp (3.06%), ArrowMark Colorado Holdings LLC (2.27%), Geode Capital Management LLC (1.20%), Fiera Capital Corp (1.28%) and Janus Henderson Group PLC (1.13%). Company insiders that own Immunomedics stock include Avoro Capital Advisors Llc, Bryan Ball and Venbio Select Advisor Llc. View institutional ownership trends for Immunomedics.

Which institutional investors are selling Immunomedics stock?

IMMU stock was sold by a variety of institutional investors in the last quarter, including Foresite Capital Management III LLC, Janus Henderson Group PLC, Morgan Stanley, Morgan Stanley, Federated Hermes Inc., Wells Fargo & Company MN, JPMorgan Chase & Co., and Rafferty Asset Management LLC. View insider buying and selling activity for Immunomedics.

Which institutional investors are buying Immunomedics stock?

IMMU stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Ghost Tree Capital LLC, State Street Corp, Geode Capital Management LLC, Squarepoint Ops LLC, Victory Capital Management Inc., Victory Capital Management Inc., and First Trust Advisors LP. Company insiders that have bought Immunomedics stock in the last two years include Avoro Capital Advisors Llc, Bryan Ball, and Venbio Select Advisor Llc. View insider buying and selling activity for Immunomedics.

How do I buy shares of Immunomedics?

Shares of IMMU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Immunomedics' stock price today?

One share of IMMU stock can currently be purchased for approximately $30.18.

How big of a company is Immunomedics?

Immunomedics has a market capitalization of $6.97 billion and generates $290,000.00 in revenue each year. The biopharmaceutical company earns $-357,190,000.00 in net income (profit) each year or ($1.84) on an earnings per share basis. Immunomedics employs 346 workers across the globe.

What is Immunomedics' official website?

The official website for Immunomedics is www.immunomedics.com.

How can I contact Immunomedics?

Immunomedics' mailing address is 300 AMERICAN RD, MORRIS PLAINS NJ, 07950. The biopharmaceutical company can be reached via phone at 973-605-8200 or via email at [email protected]

This page was last updated on 6/4/2020 by MarketBeat.com Staff